FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
insight
/
details

Next-Generation Sequencing (NGS) Technology in Hematologic Malignancies

NextEdge Admin

01 May 2024

3 min 16 sec

The integration of next-generation sequencing (NGS) technology in hematologic malignancies has revolutionized our understanding and management of these complex diseases. Hematologic malignancies pose unique challenges due to their clinical heterogeneity driven by genetic mutations. However, recent advancements in NGS have addressed several critical aspects of these challenges.

One significant obstacle is the presence of complex mutations, which can confound short-read sequencing chemistry. To tackle this issue, the integration of diverse data from multiple assays becomes imperative for comprehensive pathogenicity assessments. Furthermore, recent advances have revealed that many patients with myeloid malignancies have a germline predisposition, highlighting the importance of molecular analysis in patient care and genetic counseling.

Targeted NGS panels, encompassing both DNA and RNA-based assays, have become integral for the molecular characterization of hematologic malignancies. These panels efficiently assess genetic biomarkers, aiding in personalized treatment approaches. Additionally, non-targeted NGS approaches, such as Whole-Genome Sequencing (WGS), have been instrumental in detecting recurrent translocations and copy-number alterations, further enhancing our understanding of disease mechanisms.

For disease monitoring, NGS-based measurable residual disease (MRD) assessment has emerged as a highly reliable alternative to conventional methods like real-time quantitative PCR (RQ-PCR) and flow cytometry. This technology offers enhanced precision, enabling more effective monitoring of treatment response and disease progression.

However, challenges persist, including workflow fragmentation and manual data transfer in NGS labs, leading to longer turnaround times and increased error rates. Addressing these challenges requires the adoption of seamless, customizable workflows supported by bioinformatic analysis tools tailored to the complexity of hematologic malignancies. Selecting the right bioinformatics solution is crucial for accurate variant detection and scalability. Automated pipelines play a pivotal role in handling high volumes of data efficiently, reducing repetitive testing and streamlining the overall workflow.

The integration of NGS technology and advanced bioinformatics solutions holds tremendous promise for advancing precision medicine in hematologic malignancies. By overcoming existing challenges and leveraging the capabilities of NGS, we can significantly improve outcomes for a large population of patients afflicted with these diseases.